Roche is counting on new medicines like Hemlibra to replace falling revenue from its trio of blockbuster cancer medicines, Rituxan, Avastin and Herceptin.
ROCHE, RECENTLY received an US regulators approval for expanded use of its drug Hemlibra to include almost all patients with hemophilia A, as the Swiss drugmaker increases its focus on diseases beyond cancer to help replace revenue from older products that have lost patent protection.
The Food and Drug Administration cleared Hemlibra to treat adults, children and newborns with the genetic disorder in which blood does not clot properly, putting them at risk of dangerous bleeding.
Hemlibra can now be used for patients who have not become resistant to standard treatment, known as factor replacement therapy. It is the only preventive treatment for hemophilia A patients with and without factor VIII inhibitors that can be self-administered subcutaneously once weekly, every two weeks or every four weeks. Older treatments, sold by companies like Shire, require more frequent intravenous infusions.
Hemlibra won initial US approval last year only for hemophilia A patients with factor VIII resistance, or inhibitors. That accounted for only about 5 per cent to 7 per cent of the estimated 16,000 US hemophilia A patients. Factor VIII is a protein involved in clotting.
For a hemophilia A patient of average weight of about 140 pounds (63.4 kg), the annual list price for Hemlibra will be about $ 492,000 per year, following the initial first-year dose that costs an additional $ 38,000, a spokeswoman for Roche’s US Genentech unit said on Thursday. Dosing is based on a patient’s weight.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
MAKING SUSTAINABILITY SUSTAINABLE
Driven by stringent regulations, rising investor expectations, consumer demand, and operational considerations, MSME pharma companies need to carefully balance their sustainability goals with financial viability
New energy recovery system for tablet coaters
Upto 50 per cent less steam energy consumption
The future of pharma logistics: Trends, challenges, and opportunities
Nikhil Agarwal, President, CJ Darcl Logistics explains that the future of pharma logistics is a thrilling frontier shaped by technological advancements, regulatory challenges, and the imperative of sustainability. As the industry transforms, logistics providers must embrace innovative solutions and adapt to shifting demands
Achieving Aatmanirbharta In APIs Are We On The Right Track?
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a key goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats
Yokogawa launches OpreX Data Model Broker
A plant data transformation platform, OpreX automatically verifies discrepancies and inconsistencies in data to improve efficiency in plant construction and operation
Understanding the nuances of generics injectables
At a webinar, explaining the West Pharma's AccelTRA Components Program, industry experts explained why the use of glass vials and stoppers as primary container closure systems (CCS) has become crucial
Trending in nutraceuticals: Science meets sustainability
Zeljko Pockaj, Vice President, Global Pharmaceutical Industry, mentions the key trends that are believed to drive innovations and formulations for nutraceuticals’ development around the globe
The growth of e-pharmacies in India
Rahul Nath Choudhury, Research fellow, ICWA, explains what motivates people in the pharma industry to invest into e-pharmacies, along with various other growth factors associated with these
Xylitol and Maltitol: Low-calorie sugar alternatives
Polyols like Xylitol and Maltitol offer important health benefits. Unlike general sugar-free sweeteners, these do not have any bitter-after taste
Single-use TC gaskets and their importance
Depending on the application, gaskets are manufactured by different types of Material of Construction (MOC) such as Silicone, EPDM, Viton (FKM), Nitrile, Neoprene, PTFE, etc.